Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Hold” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average rating of “Hold” by the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $20.40.

A number of equities research analysts have commented on KROS shares. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 9,767 shares of the company’s stock, valued at $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,425 shares of company stock valued at $89,994 over the last quarter. 12.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in shares of Keros Therapeutics by 282.5% in the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock valued at $12,047,000 after buying an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Keros Therapeutics during the 2nd quarter worth $4,251,000. Caption Management LLC raised its stake in Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after acquiring an additional 291,997 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in Keros Therapeutics by 683.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after acquiring an additional 264,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after acquiring an additional 263,347 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

KROS stock opened at $10.61 on Thursday. The company’s 50 day moving average price is $10.85 and its 200 day moving average price is $13.21. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The firm has a market capitalization of $209.97 million, a price-to-earnings ratio of -3.52 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Equities analysts forecast that Keros Therapeutics will post -5.19 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.